NKF/KDOQI: Anemia in Chronic Kidney Disease

| No Comments
2.1.2 In the opinion of the Work Group, in dialysis and nondialysis patients with CKD receiving ESA therapy, the selected Hb target should generally be in the range of 11.0 to 12.0 g/dL. (Clinical Practice RECOMMENDATION)

2.1.3 In dialysis and nondialysis patients with CKD receiving ESA therapy, the Hb target should not be greater than 13.0 g/dL. (Clinical Practice GUIDELINE - MODERATELY STRONG EVIDENCE)

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target

Determining Brain Death in Adults

| No Comments

IV. Confirmatory laboratory tests (Options)

Brain death is a clinical diagnosis. A repeat clinical evaluation 6 hours later is recommended, but this interval is arbitrary. A confirmatory test is not mandatory but is desirable in patients in whom specific components of clinical testing cannot be reliably performed or evaluated. It should be emphasized that any of the suggested confirmatory tests may produce similar results in patients with catastrophic brain damage who do not (yet) fulfill the clinical criteria of brain death. The following confirmatory test findings are listed in the order of the most sensitive test first. Consensus criteria are identified by individual tests.

    1. A. Conventional angiography. No intracerebral filling at the level of the carotid bifurcation or circle of Willis. The external carotid circulation is patent, and filling of the superior longitudinal sinus may be delayed.
    2. B. Electroencephalography. No electrical activity during at least 30 minutes of recording that adheres to the minimal technical criteria for EEG recording in suspected brain death as adopted by the American Electroencephalographic Society, including 16-channel EEG instruments.
    3. C. Transcranial Doppler ultrasonography
      1. 1. Ten percent of patients may not have temporal insonation windows. Therefore, the initial absence of Doppler signals cannot be interpreted as consistent with brain death.
      2. 2. Small systolic peaks in early systole without diastolic flow or reverberating flow, indicating very high vascular resistance associated with greatly increased intracranial pressure.

    4. D. Technetium-99m hexamethylpropyleneamineoxime brain scan. No uptake of isotope in brain parenchyma ("hollow skull phenomenon").
    5. E. Somatosensory evoked potentials. Bilateral absence of N20-P22 response with median nerve stimulation. The recordings should adhere to the minimal technical criteria for somatosensory evoked potential recording in suspected brain death as adopted by the American Electroencephalographic Society.

 

American Academy of Neurology. Determining Brain Death in Adults.

 

USPSTF: Screening for Breast Cancer

| No Comments
The U.S. Preventive Services Task Force (USPSTF) recommends screening mammography, with or without clinical breast examination (CBE), every 1-2 years for women aged 40 and older.
Grade: B (recommended, fair evidence)

The USPSTF concludes that the evidence is insufficient to recommend for or against routine CBE alone to screen for breast cancer.
Grade: I (insufficient evidence)

The USPSTF concludes that the evidence is insufficient to recommend for or against teaching or performing routine breast self-examination (BSE).

Grade: I (insufficient evidence)


Screening for Breast Cancer, Topic Page. November 2003. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD.

NKF/KDOQI: Erythropoietin & Hemoglobin Target

| No Comments

2.1.3 In dialysis and nondialysis patients with CKD receiving ESA therapy, the Hb target should not be greater than 13.0 g/dL. (Clinical Practice GUIDELINE - MODERATELY STRONG EVIDENCE)

 

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target

ACC/AHA: 2009 Heart Failure Dx & Mgmt

| No Comments

3. Recommendations for the Initial Clinical Assessment of Patients Presenting With Heart Failure

Class IIa, number 9.

Measurement of natriuretic peptides (BNP and NT-proBNP) can be useful in the evaluation of patients presenting in the urgent care setting in whom the clinical diagnosis of HF is uncertain. Measurement of natriuretic peptides can be useful in risk stratification (Level of Evidence: A

3. Recommendations for Serial Clinical Assessment of Patients Presenting With Heart Failure

Class IIb, number 1.

The value of serial measurements of BNP to guide therapy for patients with HF is not well established (Level of Evidence: C)

 

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. J Am Coll Cardiol 2009; 53: 1343.

IDSA: Asymptomatic Bacteriuria in Adults

| 4 Comments

2. Pyuria accompanying asymptomatic bacteriuria is not an indication for antimicrobial treatment (A-II).

 

IDSA Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults

Recent Comments

  • Patrick: Guidelines are meant to be guidelines. In the IDSA recommendation, read more
  • Alifeya: an example, 80 y/o nursing home resident with severe dementia read more
  • Patrick: The IDSA guidelines for uncomplicated cystitis excluded studies where >2% read more
  • mbazylewicz: Does a fever (unidentified source) with no dysuria, frequency, urgency, read more